Kornimate/medical-research-clean huggingface dataset:
comparison between land-based and water-based exercises for knee osteoarthritis: randomized controlled trial

Conditions: Knee Osteoarthritis

Summary: forty six patients with knee osteoarthritis will be randomly allocated into two groups: water-based exercises and land-based exercises. both of them will receive a strengthening exercise protocol for lower limb muscles. a blind investigator will assess the patients before and immediately after, 3 months and 6 months following the interventions. the main outcomes will be pain, function and strength.

forty six patients with knee osteoarthritis will be randomly allocated into two groups: water-based exercises and land-based exercises. both of them will receive a strengthening exercise protocol for lower limb muscles. a blind investigator will assess the patients before and immediately after, 3 months and 6 months following the interventions. the main outcomes will be pain, function, physical performance and strength.

Eligibility criteria:
inclusion criteria: * moderate knee osteoarthritis (grade 2 or 3 using the kellgren-lawrence radiograph classification), diagnosed based on clinical and radiological criteria of the american college of rheumatology * no other lower limb and spine musculoskeletal disorders * independent gait * body mass index below 32 * minimum of 4 points in the pain numeric rating scale during climb and descend stairs activities exclusion criteria: * cognitive or psychological disorders * neurological disorders * history of post-traumatic knee osteoarthritis * knee pain at least 12 months * prior surgery of the lower limbs or spine * fibromyalgia * rheumatoid arthritis * cardiovascular disease * participating in exercise programs and received treatment for the knee at least 3 months
study of xl184 (cabozantinib) in adults with advanced malignancies

Conditions: Lymphoma; Cancer; Thyroid Carcinoma

Summary: the purpose of this study is to determine the best and safest dose of xl184 administered orally. xl184 is a new chemical entity that inhibits vegfr2, met and ret, kinases implicated in tumor formation, growth and migration. to determine the highest safe dose, subjects will receive different amounts of the drug. the first group of subjects will receive the lowest dose of xl184. as long as no medically unacceptable side effects are noted, the dose will be increased for the next group. when the maximum tolerated dose (mtd) is reached, at least 20 subjects with medullary thyroid cancer (mtc) will be enrolled to evaluate the effect of xl184 in this population.


Eligibility criteria:
inclusion criteria: * histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective * eastern cooperative oncology group (ecog) performance status \</= 2 * life expectancy greater than 3 months * adequate organ and marrow function * written informed consent * use of acceptable methods of contraception during the course of the study and for 3 months after completion of study * in the mtd expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent medullary thyroid cancer not appropriate for surgical resection with measurable disease as defined by recist exclusion criteria: * chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin c within 6 weeks) before the first scheduled dose of xl184 * administration of an investigational drug within 30 days of the first dose of xl184 * subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment * known brain metastases * uncontrolled intercurrent illness * pregnancy or breastfeeding * known hiv positive * known allergy or hypersensitivity to any of the components of the xl184 formulation

Keywords: advanced malignancies solid tumor medullary thyroid cancer
prospective intervention study on vitamin d in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the vast majority of cystic fibrosis (cf) patients worldwide are vitamin d insufficient. there is no evidence of benefit of vitamin d supplementation for cf patients yet. however, descriptive cross-sectional studies suggest that vitamin d might be beneficial with respect to bone health, as well as to the newly described "non-classical" functions of vitamin d such as the potential anti-diabetic and immunomodulatory effects. to prove causation, and to determine which serum vitamin d concentration is optimal for cf patients, vitamin d supplementation interventional studies are needed, such as our trial.


Eligibility criteria:
inclusion criteria: * established diagnosis of cystic fibrosis * age 6 years and more * serum 25-hydroxy vitamin d concentration at the latest visit \< 75 nmol/l exclusion criteria: * pregnancy or lactation * established diagnosis of cf-related diabetes * cf-related liver disease * status post transplantation (lung, liver or other) * long-term corticosteroid treatment per os * hypercalcaemia or kidney stones * use of tanning beds more often than once a month * at inclusion, plans to travel to a sunny location for more than 1 week during the study period * any known disorders of the endocrine system affecting vitamin d metabolism (hyperparathyroidism, malignancy, advanced renal disease) * inclusion into another study testing immunomodulatory substances
cilostazol and nimodipine combined therapy after aneurysmal subarachnoid hemorrhage (asah)

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: the investigators seek to demonstrate that the combined use of cilostazol and nimodipine will significantly decrease the rate of delayed cerebral infarction and cerebral vasospasm after cerebrovascular intervention when compared to nimodipine alone.

this research study is for people who have a brain hemorrhage, due to a ruptured aneurysm. adding the drug cilostazol to the standard care may improve outcomes after surgery. the blood within the brain following aneurysmal hemorrhage can have harmful effects on the blood vessels causing them to narrow and thus decrease blood flow; this process is called vasospasm. decreased blood flow in the brain can lead to more damage. delayed cerebral ischemia is a complication which is believed to be a consequence of reduced blood flow to the brain following this type of hemorrhage. cilostazol opens blood vessels and reduces the formation of blood clots. the standard treatment of these hemorrhages currently involves the use of nimodipine which also relaxes blood vessels and allows blood to flow more freely. the combination of these two drugs cilostazol and nimodipine may improve neurologic outcomes after surgery.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * anterior circulation aneurysm * patients who have undergone surgical intervention * absence of rebleeding or new intracranial hemorrhage noted on post-intervention ct scan * consent for study participation exclusion criteria: * non-aneurysmal subarachnoid hemorrhage * multiple ruptured aneurysms * patients with congestive heart failure * severe aneurysmal subarachnoid hemorrhage (hunt hess grade v) * active pathological bleeding * allergy to cilostazol * positive pregnancy test * coagulopathy not caused by anti-coagulant use * history of hemorrhagic complications (gastrointestinal bleeding, etc) * uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol * patients requiring anticoagulant/antiplatelet treatment following intervention (e.g. stent-assisted coiling or flow-diverting stent obliteration of aneurysm)

Keywords: delayed cerebral ischemia cerebral vasospasm cilostazol
evaluation of a simplified strategy for the long-term management of hiv infection (simpl'hiv)

Conditions: HIV-1-infection; Antiretroviral Therapy; Maintenance Therapy

Summary: the purpose of this study is to evaluate whether maintenance antiretroviral therapy could be simplified to dtg + ftc dual therapy and/or patient-centered monitoring once virological suppression is achieved. using a factorial design, the study aims to assess the efficacy of dtg + ftc dual therapy to maintain virological suppression through 48 weeks of follow-up as well as the costs of a patient-centered art laboratory monitoring.

this is a pragmatic multicentre, 2x2 factorial randomized controlled trial with 1:1:1:1 randomization to switching to dtg-based maintenance dual therapy in association with ftc or continuation of cart, and to patient-centered monitoring or continuation of standard monitoring. patients will be followed during 48 weeks.

Eligibility criteria:
inclusion criteria: 1. informed consent as documented by signature; 2. documented hiv-1 infection; 3. enrolled in the swiss hiv cohorte study (shcs) or receiving care from a medical doctor of the shcs network; 4. ≥ 18 years of age; 5. hiv-rna \<50 copies/ml at screening and for at least 24 weeks before screening on effective suppressive cart, one blip with less than 200 copies/ml being allowed during this period if followed by at least 2 results \< 50 copies/ml. 6. on standard cart at the time of inclusion, i.e.: * 2 nrtis + either 1 nnrti, 1 boosted pi or 1 insti; * nrti-sparing triple arv regimen (e.g. 1 nrti + 1 nnrti + 1 insti); * dual therapy with protease inhibitor. exclusion criteria: 1. hiv-2 infection; 2. previous art change for unsatisfactory virological response, i.e. slow initial virological suppression, incomplete suppression or rebound. change of drug or drug class for convenience or toxic effect prevention or management is allowed. note: patients with documented genotype(s) presenting only a m184v mutation remain eligible; 3. creatinine clearance \< 50ml/min; 4. asat or alat \>2.5x upper limit of the norm; 5. known hypersensitivity, intolerance or allergy to dtg or ftc; 6. known or suspected non-adherence (defined as \ 1x/week) to current treatment in the last 6 months; 7. concomitant use of drugs that decrease dtg blood concentrations including carbamazepine, oxcarbamazepine, phenytoin, phenobarbital, st john's wort and rifampicin; 8. women who are pregnant or breast-feeding; 9. a. presence of any insti-resistance. non-availability of insti resistance testing is not an exclusion criteria. b. non availability of previous routine resistance test, at least for reverse transcriptase and protease genes. note: subjects remain eligible in the absence of any previous resistance test only if they are on their first-line antiretroviral regimen; 10. evidence of acute or chronic hepatitis b virus infection based on results of serology testing.
european registry for myeloproliferative neoplasms (mpns) - update of ernest study

Conditions: Myelofibrosis

Summary: the fondazione per la ricerca ospedale di bergamo (from) decided to propose and promote the completion of ernest registry: the aim of the project is to obtain up-to-date estimates of clinical outcome of these patients in primary and secondary myelofibrosis that have been included in the 'original' ernest study. the last was conducted between 2012 and beginning of 2015 including 1292 patients with myelofibrosis, but it was interrupted in 2015 because of bankruptcy of the previous sponsor.

follow-up of patients already been registered in the ernest registry resulting alive and/or in active surveillance at november 2014 (blood 2014 124:1849) will be updated retrospectively until december 2020. data collection will be centralized at fondazione per la ricerca ospedale di bergamo (from), and performed by a web-based and electronic data capture (edc) system through ad hoc electronic case report forms (e-crfs). the e-crfs system will be pre-filled with pre-existing data collected from cases already entered in the registry. information on therapies received and outcome events occurred (in term of death, evolution to acute leukemia, secondary cancer and cardiovascular complications) until december 2020 will be recorded by authorized participating investigators.

Eligibility criteria:
inclusion criteria: * previous registration in the ernest registry (2012 - 2014) * diagnosis of mf performed between january 2001 and 2012 december * signed informed consent to continue participation in the registry exclusion criteria: none

Keywords: survival acute leukemia second cancer cardiovascular complication update disease management
uterine rupture during labor among women with a prior cesarean delivery

Conditions: Uterine Rupture; Mode of Delivery

Summary: although a rare event, uterine rupture during labour is one of the most serious obstetric complications because of the dramatic maternal-fetal consequences that can result. identifying the risk factors associated with uterine rupture would enable gynecologists to provide patients with risks of uterine rupture in the event of attempted vaginal delivery. the aim of our study is to determine risks factors for uterine rupture during labour in patients with a previous cesarean delivery who have not given birth since and to assess the occurrence of maternal-fetal comply-cations compared to patients with a previous cesarean delivery without uterine rupture.


Eligibility criteria:
inclusion criteria: * singleton pregnancy \> 24 weeks of gestation * second or multiparous with a previous cesarean section without vaginal delivery since * cephalic presentation or completed breech * uterine rupture during labor exclusion criteria: * incomplete uterine rupture * multiple gestation * transverse presentation or complete breech * vaginal delivery after cesarean * non-low transverse cesarean section * placenta praevia * antepartum intrauterine fetal death * history of uterine surgery (myomectomy)

Keywords: risks factors uterine rupture after a previous cesarean delivery vaginal birth after cesarean prior cesarean perinatal outcome
intraoperative renal desaturation and postoperative acute kidney injury

Conditions: Postoperative Acute Kidney Injury

Summary: the aim of this study is to investigate the changes in renal regional oxygen saturation (rso2) monitored by near-infrared spectroscopy (nirs) and its relationship with the occurrence of postoperative aki.

postoperative acute kidney injury (aki) is a severe complication after liver resection and contributes to increased morbidity and mortality. advanced age reduces renal autoregulatory capacity due to physiological and functional changes, thus render the elderly to suffer postoperative aki and probably the consequent chronic kidney disease. thus, it is essential to identify those patients at high risk to develop postoperative aki to optimize perioperative prevention and protection strategies. despite the multiple risk factors and potential mechanisms that have been identified, the diagnosis of postoperative aki depending on serum creatinine changes have been delayed for early identification of postoperative aki. it is of great interest to develop target strategies for close motoring of renal function. this study is a prospective cohort study to investigate the associations between intraoperative renal desaturation measured by nirs and postoperative aki. the investigators intend to access the optimal threshold values of renal rso2 for predicting postoperative aki. desaturation of renal rso2 will be defined by the severity and duration of nirs values during the surgical process. the principal clinical outcome of the study is postoperative aki, defined as an absolute increase in serum creatinine of 0.3 mg/dl within 48 hours or a 1.5-fold increase from preoperative baseline within seven days after surgery, according to the kidney disease: improving global outcomes (kdigo) criterion.

Eligibility criteria:
inclusion criteria: * elderly patients (defined as 60 years of age or older) scheduled for elective liver resection exclusion criteria: * emergency surgery * liver transplantation * preoperative hemodialysis * bmi \> 30 * renal depth (distance from the capsule of the kidney to the skin surface) \> 4 cm * unable or failed to sign the informed consent

Keywords: liver resection elderly renal oxygen saturation near-infrared spectroscopy
perfusion scanning's for kidney tumors

Conditions: Kidney Cancer

Summary: to investigate the ability of perfusion ct/us-scanning to facilitate recognition of different tumour sub-types in small renal masses less than 7 cm by non-invasive imagining technology.

the number of diagnoses of renal cell carcinoma has increased over the past two decades because of the incidental detection of small renal tumours resulting from increased use of computed tomography \[1,2\]. there are distinct subtypes of renal cell carcinoma (rcc), and the biological aggressiveness and prognoses for these subtypes have been documented. clear-cell rcc is the most common rcc subtype, followed by papillary rcc, chromophobe rcc and unclassified rcc. collecting duct carcinoma is a rare and highly malignant type of rcc. although most enhancing renal masses in adults are rcc, a significant percentage are benign (commonly oncocytoma), and these benign tumours cannot be distinguished from malignant tumours based on our standard imaging technology alone. benign primary renal masses include simple renal cysts, psuedotumours, angiomyolipomas, oncocytomas, juxtaglomerular tumours, multilocular cystic nephromas, mesoblastic nephromas and papillary adenomas. in a recent surgical series of 228 patients who underwent partial or radical nephrectomy with lesions ≤4 cm, 26.3% were benign \[3\]. the relatively high percentage of patients with benign renal cortical neoplasms who undergo surgery highlights the importance of new diagnostic technology in avoiding over-treatment. ultrasound (us) and ct scanning guided biopsy is the most commonly used method to diagnosis rcc. the sensitivity of biopsy for small masses (≤3 cm) is lower than for large masses \[4\]. sensitivity is limited by false-negative results, which are due to a failure to properly target a small mass or the presence of impossible-to-differentiate benign from malignant cells due to insufficient cells, morphological overlap or cellular heterogeneity. non diagnostic biopsy is not necessary benign, as repeated biopsy reveals malignancy diagnosis in the majority\[5\]. there is no radiologic criteria consistent with oncocytoma because of a lack of sensitivity and specificity \[6\]. mr-scanning and ct-scanning are not feasible diagnostic methodologies for oncocytoma because of the possibility of overlapping results from oncocytoma and rcc \[7\]. hypotheses: to investigate the ability of perfusion ct/us-scanning to facilitate recognition of different tumour sub-types in small renal masses less than 7 cm by non-invasive imagining technology. purpose: to recognize different subtype's renal tumor by non invasive scanning. design: a descriptive study

Eligibility criteria:
inclusion criteria: 1. patients suspecting to have renal tumors by ct/ul-scanning. 2. patients age between 35 and 75 years 3. normal renal function 4. can read and understand danish 5. non - metastasis disease detected by scanning exclusion criteria: 1. patients have a nephropathy (defined as e-gfr less than 50 ml/min/1.73cm³). 2. previous allergic reaction to intravenous contrast material. 3. untreated hyperthyroidism. 4. pregnancy.
food antigen in eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: the relationship or effect of food antigen (wheat based soy sauce) in eosinophilic esophagitis. it is believed that when food antigens are exposed to the esophageal tissue it starts an chronic allergy-based inflammation. this will be analyzed with the esophageal biopsies and the mucosal impedance probe.

one of the putative mechanisms of eosinophilic esophagitis is exposure of food antigens to antigen recognition cells in the esophageal mucosa that initiates a chronic allergy-based inflammatory response . it is believed that this exposure is facilitated through dilation of the intercellular spaces (dis) between esophageal epithelial cells (termed spongiosis). this is substantiated by several studies which have demonstrated that: first, dis is commonly found in biopsies from patients with active eoe and reverses with steroid therapy; second, dis correlates to physiologic demonstration of increased esophageal epithelial permeability as shown through transepithelial small molecule flux in mucosal biopsies appraised in ussing chambers and increased conductivity of electric current as measured in a mucosal impedance probe (katzka, et al., in press, clin gastroenterol hepatol). although these mechanisms make intuitive sense, no one has shown the presence of food antigen in esophageal mucosa after ingestion and the correlation of this presence to dilation of intercellular spaces.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors. * patients previously diagnosed with eosinophilic esophagitis and are now in histologic remission due to treatment and have \<15 eos hpf. exclusion criteria * acute allergy to wheat or soy * currently taking steroids * inability to read due to: blindness, cognitive dysfunction, or english language illiteracy

Keywords: eosinophilic
drug compliance and quality of life in patients with heart failure dosed with either once-daily or twice-daily coreg

Conditions: Chronic Heart Failure

Summary: the purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (coreg) twice a day.

study further study details: primary outcome: pill-taking compliance (total doses taken versus total doses prescribed) expected total enrollment: 400 subjects at 56 study sites in the u.s. study start: october 2005 this is a 5-month double-blind treatment study of male and female subjects with stable mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of heart failure. eligibility: must be stable on treatment with coreg ir at a standard dose: 6.25, 12.5, 25 mg twice a day.

Eligibility criteria:
inclusion criteria: * ability to read english * stable symptoms of mild to severe heart failure * stable medical regimen for heart failure * on a stable dose of coreg for at least 2 months * lvef ≤40% within the previous 24 months exclusion criteria: * uncorrected obstructive or regurgitant valve disease * complex congenital heart disease * recent icd or pacemaker placement * recent coronary artery bypass surgery or stroke * candidate for heart transplanct within 5 months of study start * present or planned use of mao inhibitors, alfpha-blockers, combined alpha-beta blockers, any class i/ii anti-arrythmnic agents, (amiodarone may be used if ≤ 200mg/day). use of intravenous vasodilator/inotropic agents.

Keywords: chronic heart failure left ventricular systolic dysfunction
normative database of the retinal nerve fiber layer thickness measured by the cirrus hd oct in asians

Conditions: Glaucoma

Summary: the normal range of retinal nerve fiber layer thickness might be different between asians and caucasians. however, the recently developed imaging device such as the cirrus hd oct includes only the caucasian data. so, the investigators want to find its normal range of in asians.

characteristics of various ocular parameters are influenced by race. because the retinal nerve fiber layer (rnfl) thickness is crucial in detecting early glaucomatous changes, its normal range is also important. even though the normal range of rnfl thickness might be different according to race, the recently developed imaging device such as the cirrus hd oct includes only the caucasian data. in the present study, we want to measure the rnfl thickness using the cirrus hd oct in normal asian eyes and to determine its normal range in asians.

Eligibility criteria:
inclusion criteria: * normal subjects * good quality of the oct images (signal intensity \> 8) exclusion criteria: * any ocular history * dm

Keywords: retinal nerve fiber layer glaucoma myopia